- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02365987
The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety (INTERFAT)
The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety: a Randomised Controlled Trial. The INTER-FAT Study
Study Overview
Status
Conditions
Detailed Description
Aim: The current study aims to investigate the acute effects of commercially relevant interesterified 'hardstock' versus the corresponding un-interesterified blend on postprandial lipaemia, glycaemia, insulinaemia and gut hormone responses. Due to the previously observed differences in gut hormones following interesterified palm oil and un-interesterified palm oil by our group, we will also explore acute effects of these fats on satiety and rates of gastric emptying.
Hypothesis: Interesterification of a palm kernel and palm stearin fat blend, to produce a fat with a higher proportion of palmitic acid in the middle position of the TAG (but the same fatty acid composition), will alter postprandial lipid and glucose metabolism. It is also hypothesised that differences in rates of absorption between the test fats will influence gut hormone responses and feelings of satiety.
Subjects: Participants will include 10 healthy male volunteers. In order to determine the 'typical' response to the test fats, subjects must not be affected by metabolic syndrome in any way (obesity, dyslipidemia, insulin resistance or hypertension), they must be non-smokers (since smoking influences postprandial lipaemia), and be aged between the ages of 18 and 45 years (since above this age metabolic changes may take place that may affect the way that the body digests and metabolises lipids). Male volunteers have been selected as they elicit a higher postprandial lipaemic response to a given fat load and therefore are more sensitive to dietary manipulation.
Power calculation: A sample size of 10 has 80% power to detect a difference between means of 112.74 units in area under the curve in plasma TAG with a significance level (alpha) of 0.05 (two-tailed).
Expected value:
The study will provide novel information on the acute effects of commercially relevant spreads on postprandial lipaemia and satiety. It will also explore possible mechanisms for the predicted reduced lipaemia following the interesterified fat from measurements of gastric emptying.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SE1 9NH
- Diabetes and Nutritional Sciences Division, School of Medicine, Kings College London
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18-45
- Male
- Healthy (free of diagnosed diseases listed in exclusion criteria)
- Able to understand the information sheet and willing to comply with study protocol
- Able to give informed consent
Exclusion criteria:
- Medical history of myocardial infarction, angina, thrombosis, stroke, cancer, liver or bowel disease or diabetes
- Body mass index < 20 kg/m2 or > 35 kg/m2
- Plasma cholesterol ≥7.5 mmol/L
- Plasma triacylglycerol > 3 mmol/L
- Plasma glucose > 7 mmol/L
- Blood pressure ≥160/100 mmHg
- Current use of antihypertensive or lipid lowering medications
- Alcohol intake exceeding a moderate intake (> 28 units per week)
- Current cigarette smoker
- ≥ 20% 10-year risk of cardiovascular disease as calculated using risk calculator
- Ingestion of paracetamol in the preceding 24 hrs to study days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Interesterified
Interesterified blend of palm kernal and plam stearin.
50g fat.
|
50g fat provided as interesterified palm kernal and palm sterin blend in a single meal
Other Names:
|
|
Active Comparator: Un-interesterified
Un-interesterified blend of palm kernal and plam stearin.
50g fat.
|
50g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postprandial lipaemia (Postprandial plasma triacylglycerol concentrations)
Time Frame: Postprandial 4 hrs
|
Postprandial plasma triacylglycerol concentrations
|
Postprandial 4 hrs
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycemia (Postprandial plasma glucose and insulin concentrations)
Time Frame: Postprandial 4 hrs
|
Postprandial plasma glucose and insulin concentrations
|
Postprandial 4 hrs
|
|
Gut hormones (Postprandial gut peptide YY and glucose-dependent insulinotropic polypeptide concentrations)
Time Frame: Postprandial 4 hrs
|
Postprandial gut peptide YY and glucose-dependent insulinotropic polypeptide concentrations
|
Postprandial 4 hrs
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Satiety (Postprandial visual analogue scales)
Time Frame: Postprandial 4 hrs
|
Postprandial visual analogue scales
|
Postprandial 4 hrs
|
|
Gastric emptying (Postprandial paracetamol concentrations)
Time Frame: Postprandial 4 hrs
|
Postprandial paracetamol concentrations
|
Postprandial 4 hrs
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sarah EE Berry, BSc,MSc,PhD, King's College London
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BDM/14/15-26
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Men
-
University Hospital, Clermont-FerrandService de Biologie de la Reproduction : AMP-CECOS; EA 975, Laboratoire de BDR and other collaboratorsCompletedHealthy Volunteers | Normocholesterolaemic Men | Normozoospermic MenFrance
-
Paulista UniversityCompleted
-
Heinrich-Heine University, DuesseldorfThe Cranberry InstituteCompleted
-
H. Lundbeck A/SCompleted
-
Yonsei UniversityCompletedHealthy MenKorea, Republic of
-
AstraZenecaCompleted
-
USDA Beltsville Human Nutrition Research CenterCompleted
-
Bio-Thera SolutionsNot yet recruiting
-
Mabscale, LLCActive, not recruitingHealthy MenRussian Federation
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR)Completed
Clinical Trials on Interesterified blend of palm kernal and plam stearin
-
King's College LondonCompletedHealthy Adults | Postmenopausal WomenUnited Kingdom